Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
A vision-language model trained on more than 400,000 CT volumes paired with radiology reports extracted physiological signals far beyond each scan's original clinical question, showing associations with 35 laboratory measurements and 351 diagnosis categories. It outperformed image-only models and organ-measurement baselines at predicting later diagnoses, with the strongest performance for heart failure, cirrhosis, and acute kidney failure. Direct comparison against human radiologists has not yet been performed.
Cala Health has launched the kIQ Plus nationwide in the US, a wrist-worn neuromodulation device that delivers patterned electrical stimulation through the skin to peripheral nerves for temporary relief of hand tremor in essential tremor and Parkinson's disease. The system adds three selectable stimulation modes and a mandatory calibration step before each session that reads the user's current tremor and adjusts output accordingly. Company-cited data presented at the American Academy of Neurology reported that 76% to 89% of patients achieved at least a 1-point reduction on the clinician-rated TETRAS scale, though study size and mean effect were not disclosed.
Bexorg has received up to $28.3 million from ARPA-H to extend its BrainEx platform, which perfuses intact donated human brains, from 24 hours of viable study time to as long as two weeks across a 36-month, three-phase project. The longer window would allow repeated dosing, sustained drug exposure and longitudinal molecular measurement within intact human neural and vascular tissue. For neurodegenerative disease research, where candidate therapies routinely fail between preclinical promise and clinical trials, the platform offers human-specific pharmacological data before first-in-human dosing.
A post hoc reanalysis of Alterity's 77-patient Phase 2 trial of ATH434 in multiple system atrophy reports a 52% slowing of functional decline at the 50 mg dose after adjusting for baseline disease severity using cerebrospinal fluid neurofilament light chain. The statistical model was introduced after the trial began, the 75 mg dose did not reach significance, and the primary imaging endpoint measuring iron in the substantia nigra was not met. The work is relevant to longevity research as an early test of whether modulating reactive iron can alter the trajectory of a rapidly progressing neurodegenerative disease.
German biotech MODAG received CPHI Milan's API Development and Innovation award for developing a CE-certified cerebrospinal fluid test that detects pathological alpha-synuclein aggregates alongside emrusolmin, a small molecule binding the same protein species. The drug is in a Phase 2 trial in multiple system atrophy run by Teva, with no efficacy results reported to date. The pairing illustrates a diagnostic-first approach to neurodegeneration, where confirming the underlying pathology precedes and defines treatment.
At the 4th Roundtable of Longevity Clinics, chaired by Buck Institute CEO Eric Verdin, clinic founders converged on a shift from one-off diagnostic snapshots toward a cycle of measurement, intervention, and re-measurement over time. Panellists also described a retreat from single biological age scores in favour of organ-system-level assessment, alongside growing engagement from health and life insurers.
Veradermics will report Part A topline results from study 304, a 536-participant phase 3 trial of VDPHL01, an extended-release oral minoxidil formulation for mild-to-moderate pattern hair loss. The company states the formulation blunts the high peak plasma concentrations associated with immediate-release oral minoxidil while prolonging time above the threshold associated with hair growth. Co-primary endpoints at month 6 are change in non-vellus target area hair count and participant-reported improvement on the AAIRS scale.
XellSmart's off-the-shelf cell therapy XS411 met primary safety and tolerability endpoints in a nine-participant Phase I dose-escalation study in moderate-to-advanced Parkinson's disease, with no dose-limiting toxicities, no graft-induced dyskinesia and no aberrant cellular overgrowth on MRI. The company reports OFF-state MDS-UPDRS Part III improvements exceeding 30 points at six months and more than five additional hours of good ON time per day, with 18F-DOPA PET uptake at transplant sites consistent with graft survival and restored dopamine synthesis. A randomized multicenter Phase II trial in China has enrolled 30 participants.
A study in the Journal of Applied Gerontology examines how adult day service providers in Ohio describe the operational and participant-engagement obstacles that persist after the COVID-19 period, alongside the solutions they identify. Adult day services function as a core home- and community-based support that sustains older adults outside institutional settings, and the authors note that limited state-level evidence constrains efforts to strengthen provider capacity.
Researchers reporting in Aging Cell identified MTR4, an RNA helicase, as a regulator of senescence in the endothelial cells lining blood vessels. MTR4 protein levels fall with age through accelerated ubiquitin-proteasome degradation driven by SYVN1, and restoring MTR4 partially reversed senescent features and reduced inflammatory secretions in human endothelial cells. Because senescent vessel-lining cells release these compounds directly into circulation, the pathway is relevant to vascular aging and age-related cardiovascular disease.
BodySpec has opened a retail DEXA scanning location in Oakland offering roughly 12-minute body composition scans for under $60, reporting fat mass, visceral fat, lean muscle and bone density. The company positions the service against the rapid uptake of GLP-1 receptor agonists, citing evidence that 25 to 40 percent of weight lost on these drugs can be lean tissue. Muscle and bone mass are established predictors of functional independence and mortality risk, yet have historically been measured only inside clinical settings.
VectorY has expanded its Phase 1/2 PIONEER-ALS trial of VTx-002 from 12 to 36 participants before any efficacy data is available, citing rapid enrollment and site activation. VTx-002 is a vectorized antibody designed to produce sustained antibody expression within the central nervous system against TDP-43, the protein that aggregates abnormally in up to 97% of ALS cases. The open-label, placebo-free design means the larger cohort increases biomarker and functional observations without establishing clinical benefit.